Performance analysis of Relmada Therapeutics (RLMD)
Annual Return
Over the past 3 years, RLMD has had an average annual return of +31.42%, outperforming the benchmark SPY, which returned +22.77% annual.
Over the past 5 years, RLMD has had an average annual return of -26.73%, underperforming the benchmark SPY, which returned +14% annual.
Over the past 10 years, RLMD has had an average annual return of -5.28%, underperforming the benchmark SPY, which returned +15.53% annual.
Since Oct 9, 2014, RLMD has had an average annual return of -17.50%, underperforming the benchmark SPY, which returned +14.38% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +32.88% | +830.23% | -87.45% | +18.51% | -84.50% | -29.76% | -17.76% | +747.38% | +53.32% | -31.16% | -56.40% | -83.87% |
| 2014 | |||||||||||
| +2.65% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.50% | +28.40% | +52.58% | +8.07% | -4.10% | -10.97% | +32.87% | ||||||
| 2025 | -32.56% | -25.86% | +4.65% | +17.78% | +133.96% | -20.16% | +4.04% | +79.61% | +80% | +12.31% | +99.73% | +7.10% | +830.23% |
| 2024 | -4.96% | +55.76% | -24.06% | -21.69% | -17.58% | +0% | +21.93% | -23.43% | +15.52% | +7.46% | -13.19% | -82.80% | -87.45% |
| 2023 | +16.26% | -11.31% | -37.25% | +11.50% | +12.71% | -13.40% | +6.63% | +29.03% | -11.25% | -0.40% | -17.37% | +67.48% | +18.51% |
| 2022 | -18.36% | +11.53% | +31.60% | -6.98% | -25.16% | +1.06% | +34.80% | +13.85% | +27.03% | -82.74% | -27.22% | -24.94% | -84.50% |
| 2021 | +1.90% | +2.01% | +5.60% | +9.52% | -10.29% | -7.46% | -18.77% | -8.04% | +9.60% | -10.44% | -23.91% | +26.14% | -29.76% |
| 2020 | +13.72% | +9.98% | -30.08% | +23.02% | +14.90% | -7.18% | -18.72% | -1.91% | +5.43% | -17.77% | +14.96% | -9.80% | -17.76% |
| 2019 | +19.95% | -3.61% | +33.03% | +2.30% | +38.12% | -25.85% | +18.65% | +15.92% | +0.47% | +173.19% | +14.88% | +21.24% | +747.38% |
| 2018 | -0% | -6.64% | +26.94% | +64.18% | -6.20% | -26.24% | +18.83% | -24.91% | +24.29% | +7.14% | -3.40% | -0.78% | +53.32% |
| 2017 | +10.11% | -32.58% | +11.19% | +15.60% | -3.92% | -17.98% | -0% | -7.37% | +25.05% | -15.42% | -6.58% | +0% | -31.16% |
Drawdown analysis of Relmada Therapeutics (RLMD)
The maximum drawdown for the RLMD was -99.66%, occurring on Mar 3, 2025. This drawdown has not yet recovered.
The current RLMD drawdown is -91.37%.
Since Oct 9, 2014 RLMD has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 2 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.66% | Mar 16, 2015 | 2505 | Mar 3, 2025 | Ongoing | Ongoing | Ongoing |
| -30.17% | Oct 31, 2014 | 71 | Feb 13, 2015 | 20 | Mar 16, 2015 | 91 |
| -3.22% | Oct 10, 2014 | 2 | Oct 14, 2014 | 11 | Oct 29, 2014 | 13 |